Frontiers in nutrition · 2026
Improvement of residual dizziness associated with a low-dose vitamin D-calcium combination (Caltrate D) supplementation in female patients with benign paroxysmal positional vertigo after successful repositioning: an 8-week retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Han Weiwei, Li Ange, Fan Zhenyi, Guan Qiongfeng, Liu Xiaoxia, Fan Weinv, Wu Yunqin
Аннотация
BACKGROUND: Residual dizziness (RD) is a common and debilitating symptom following successful canalith repositioning procedure (CRP) for benign paroxysmal positional vertigo (BPPV). Currently, no effective pharmacological treatment exists for this condition. Our previous work identified low serum 25-hydroxyvitamin D [25(OH)D] as an independent risk factor for RD. This study therefore evaluated whether 8-week supplementation with Caltrate D was associated with improvement in RD.
METHODS: Female patients with primary BPPV who achieved successful CRP but still complained of RD at day 7 post-CRP and had serum 25(OH)D < 20 ng/mL were enrolled. Patients who took Caltrate D for 8 weeks formed the treatment group, while those who received no vitamin D or calcium supplementation served as the control group. The primary outcome was the improvement rate of the Dizziness Handicap Inventory (DHI) total score at 4 and 8 weeks. Secondary outcomes included duration of RD.
RESULTS: Forty-three patients in the treatment group and 48 in the control group completed the study. At 4 and 8 weeks, DHI improvement rates were significantly higher in the treatment group than in the control group (56.2% ± 10.8% vs. 44.4% ± 11.8 and 77.6% ± 6.34% vs. 66.9% ± 9.8%, respectively; both p < 0.001). The median RD duration was also significantly shorter in the treatment group (12 days, IQR 7-18 vs. 19 days, IQR 12-24; p = 0.007) than in the control group.
CONCLUSION: In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration. Prospective studies are warranted to confirm these observations.
METHODS: Female patients with primary BPPV who achieved successful CRP but still complained of RD at day 7 post-CRP and had serum 25(OH)D < 20 ng/mL were enrolled. Patients who took Caltrate D for 8 weeks formed the treatment group, while those who received no vitamin D or calcium supplementation served as the control group. The primary outcome was the improvement rate of the Dizziness Handicap Inventory (DHI) total score at 4 and 8 weeks. Secondary outcomes included duration of RD.
RESULTS: Forty-three patients in the treatment group and 48 in the control group completed the study. At 4 and 8 weeks, DHI improvement rates were significantly higher in the treatment group than in the control group (56.2% ± 10.8% vs. 44.4% ± 11.8 and 77.6% ± 6.34% vs. 66.9% ± 9.8%, respectively; both p < 0.001). The median RD duration was also significantly shorter in the treatment group (12 days, IQR 7-18 vs. 19 days, IQR 12-24; p = 0.007) than in the control group.
CONCLUSION: In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration. Prospective studies are warranted to confirm these observations.